Deals
Teva Is Said to Draw Interest From Recipharm, EMS for Medis Unit
- Sale of Teva’s Medis business could fetch about $500 million
- Business has attracted other bidders such as buyout firms
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd.’s Medis unit has attracted interest from companies including Recipharm AB and Brazil’s EMS, people with knowledge of the matter said, in a potential asset sale that would help the troubled Israeli drugmaker reduce debt.
Recipharm and EMS are competing with other bidders including private equity firms for the business, the people said, asking not to be identified because the matter is private. Medis, an Icelandic unit that develops generic drugs for other companies, could fetch about $500 million in a sale, the people said.